IGF-1 LR3 vs Kisspeptin-10
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
IGF-1 LR3
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified version of IGF-1 with extended half-life and enhanced potency. The modifications prevent binding to IGF binding proteins, increasing bioavailability.
Full details →Kisspeptin-10
Kisspeptin-10 is the active fragment of kisspeptin, a hormone that plays a crucial role in initiating puberty and regulating reproductive function. It acts upstream of GnRH in the hypothalamic-pituitary-gonadal axis.
Full details →Side-by-Side Comparison
| Aspect | IGF-1 LR3 | Kisspeptin-10 |
|---|---|---|
| Mechanism | Binds to IGF-1 receptors to promote protein synthesis, muscle growth, and fat metabolism. The LR3 modification (13 amino acid extension and arginine substitution) extends half-life from minutes to 20-30 hours. | Binds to KISS1R receptors in the hypothalamus, stimulating GnRH neurons to release GnRH. This triggers the downstream cascade of LH, FSH, and sex hormone production. |
| Typical Dosage | Research protocols typically use 20-100mcg daily, often divided into multiple injections or administered bilaterally to target muscles. | Research protocols vary widely. Studies have used IV boluses of 1-10mcg/kg or subcutaneous administration. Clinical applications still being developed. |
| Administration | Intramuscular injection (site-specific growth) or subcutaneous for systemic effects. Often cycled 4-6 weeks on, equal time off. | IV or subcutaneous injection. Has very short half-life requiring frequent administration or continuous infusion for sustained effects. |
| Side Effects | Hypoglycemia, joint pain, water retention, potential jaw/hand growth with extended use, and injection site reactions. | Limited data. May cause flushing, increased heart rate, and changes in libido. Generally well-tolerated in studies. |
| Best For |